ChartRow logo
Data provided bySource: Twelve Data
BBIO
$76.80-0.72%
as of close, Nov 17, 2026
☾ AH $76.80 -0.72%
PeersASNDRVMDARGXINCYRPRXGH
Share this page

BBIO — BridgeBio Pharma Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in BBIO be worth today? →
BBIO returns: By year · By month · By week · Trailing

Price data

Price
$76.80
YTD price return
+0.41%
YTD total return
+0.41%
Market cap
15B
Enterprise value
16.1B
Shares outstanding
194.8M
52W low
$62.50
52W high
$93.42
From 52W high
-17.79%
From 52W low
+22.88%
52W range
46%$62.50–$93.42
Beta
0.98

Volume

Rel volume
1.01×
30D volume
2.8M
30D $ vol
200M

Insider trading

Insider net 1W
none
Insider net 1M
−$146K
Insider net 3M
−$837K
Insider net 1Y
−$76.5M

Form 4 transactions by trade date, as filed; latest on file 2026-10-30.

Fundamentals

Sales (ttm)
945.5M
Sales/share
$4.85
EPS (ttm)
-$2.90
FCF (ttm)
-369.8M
FCF/share
-$1.90
Book value/share
-$8.53
Net margin
-59.84%
ROA
-26.17%
Current ratio
2.09

Growth (CAGR, ttm) · 10Y

Sales
+167.45%+364.45%+75.42%n/a
Shares
+1.09%+3.84%+5.77%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+164.57%+347.26%+65.85%n/a
Price
+14.81%+37.95%+10.75%n/a
Total return
+14.81%+37.95%+10.75%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-26.5×
Fwd P/E
-283.0×
P/S (ttm)
15.8×
P/B (mrq)
-9.0×
EV/Sales (ttm)
17.0×
FCF yield (ttm)
-2.47%
Buyback yield (realized, 1y)
-1.09%
Shareholder yield (realized, 1y)
-1.09%
Buyback yield (cash, ttm)
1.69%
Shareholder yield (cash, ttm)
1.69%

Vs own 10Y history

P/S
7th

Bar = where today’s multiple sits in BBIO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.72%
5D
-2.38%
1M
+15.68%
3M
-3.87%
YTD
+0.41%
1Y
+14.80%
5Y
+66.59%
1D
-0.72%
5D
-2.38%
1M
+15.68%
3M
-3.87%
YTD
+0.41%
1Y
+14.80%
5Y
+66.59%

Fundamentals#

Revenue

5Y CAGR +127.4%5Y CAGR +127.4%YoY +192.6%
$945.5M TTM$353.2M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$364.2M TTM−$11.6M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$2.90 TTM−$0.42 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$369.8M TTM−$44.5M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$369M, capex −$835K

Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$44.2M, capex −$290K

Shares (diluted)

5Y +62.3%5Y +62.3%YoY +2.2%
195M TTM196M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$565.8M TTM−$56.7M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full BBIO financials →

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.

Palo Alto, CA·999 employees·Biotechnology·bridgebio.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding BBIO#

22 of the 193 ETFs ChartRow carries live hold BBIO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF1.0%
IBBiShares Biotechnology ETF1.0%
VBKVanguard Small-Cap Growth ETF0.4%
IWPiShares Russell Mid-Cap Growth ETF0.3%
VBVanguard Small-Cap ETF0.2%
VHTVanguard Health Care ETF0.2%
VXFVanguard Extended Market ETF0.2%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%